Effects of lovastatin on the immune system

American Journal of Cardiology

Volumn 80, Issue 10, 1997, Pages 1391-1394

  Muldoon, Matthew F ^a   Flory, Janine D ^b   Marsland, Anna ^b   Manuck, Stephen B ^b   Whiteside, Theresa L ^b   Rabin, Bruce ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CYTOTOXICITY; DISEASE ASSOCIATION; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNE FUNCTION TEST; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT PLANNING;

ADULT; ANTICHOLESTEREMIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; IMMUNE SYSTEM; LOVASTATIN; MIDDLE AGED;

EID: 0030728924     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00695-4     Document Type: Article

References (20)

1. Cults JL, Bankhurst AD. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme a reductase by lovastatin. Int J Immunopharmac 1989;11:863-869.
2. Chakrabarti R, Engleman EG. Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. J Biol Chem 1991;266:12216-12222.
3. Tabacik C, Aliau S. Cholesterogenesis and cell division in phytohemagglutinin-stimulated human lymphocytes: a comparative study with several inhibitors. Biochem Biophys Acta 1989;1011:149-157.
4. Law RE, Stimmel JB, Damore MA, Carter C, Clarke S, Wall R. Lipopolysaccharide-induced NF-κB activation in mouse 70Z/3 pre-B lymphocytes is inhibited by mevinolin and 5′-methylthioadenosine: roles of protein isoprenylation and carboxyl methylation reactions. Molecul Cell Biol 1992;12:103-111.
5. Cutts JL, Bankhurst AD. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol 1990;145:244-252.
6. Linna J, Moke M, Chen HW. Isoprenoid formation and cell-mediated immunological functions. In: Friedman H, Specter S, Klein TW, eds. Drugs of Abuse, Immunity, and Immunodeficiency. New York: Plenum Press, 1991: 269-278.
7. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Want XM, Chia D, Terasaki PI, Sabad A, Cogert GA, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-627.
8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-1389.
10. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60.
11. Muldoon MF, Herbert TB, Patterson SM, Kameneva M, Raible R, Manuck SB. Effects of acute psychological stress on serum lipids, hemoconcentration, and blood viscosity. Arch Int Med 1995;155:615-620.
12. Lewis DE, Rickman WJ. Methodology and quality control for flow cytometry. In: Rose NR, Conway de Macario E, Fahey JL, Friedman H, Penn GM, eds. Manual of Clinical Laboratory Immunology. 4th Edition. Washington, DC: American Society of Microbiology, 1992:164-173.
13. Birmaher B, Rabin BS, Garcia MR, Jain U, Whiteside TL, Williamson DE, Al-Shabbout M, Nelson BC, Dahl RE, Ryan D. Cellular immunity in depressed, conduct disorder, and normal adolescents - role of adverse life events. J Am Acad Child Adol Psychiatry 1994;33:671-678.
14. Whiteside TL, Herberman RB. Measurements of natural killer cell members and function in humans. In: Phillips MJ, Evans EE, eds. Neuroimmunology: Methods in Neuroscience. Vol. 24. Orlando: Academic Press, 1994: 10-23.
15. Stulnig T, Maczek C, Bock G, Majdic O, Wick G. Reference intervals for human peripheral blood lymphocyte subpopulations from 'healthy' young and aged subjects. Int Arch Allergy Immunol 1995;108:205-210.
16. Grünler J, Ericsson J, Dallner G. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochem Biophys Acta 1994;1212:259-277.
17. Pentikainen PJ, Saraheimo M, Schwartz JI, Amin RD, Schwartz MS, Brunner-Ferber F, Rogers JD. Comparative pharmacokinetics of lovastatin, simvastatin, and pravastatin in humans. J Clin Pharmacol 1992;32:136-140.
18. Curtiss LK. Cholesterol, apolipoprotein E, and immune cell function. In: Cummingham R, ed. Nutritional Modulation of Immune Response. New York: Marcel Dekker, 1995:169-181.
19. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today 1995;31:596-599.
20. Muldoon MF, Kritchevsky SB, Evans RW, Kagan VE. Serum total antioxidant activity in relative hypo- and hypercholesterolemia. Free Rad Res 1996; 25:239-245.